MEDICAL ethicsMEDICAL logicAlzheimer's disease (AD) is an incurable, progressive deterioration that ends, eventually, in death. For many years, AD's hallmark etiological feature was beta-amyloid plaque accumulation in the brain, but, to date, costly drugs designed to redu...
fecal matter transplant from healthy donors into AD patients, microbiome modifying drugs, and direct targeting of gut microbiome controlled neuroinflammatory pathways may potentially be disease modifying therapeutic strategies and may reduce amyloid, tau, and neurodegeneration...
Research is ongoing into how and why nerve cells in the brain die due to Alzheimer’s disease. Currently, several proteins are known to be involved: amyloid-beta, tau and beta-lipoproteins. In Alzheimer’s disease, amyloid-beta is misshapen and consequently forms sticky clum...
fecal matter transplant from healthy donors into AD patients, microbiome modifying drugs, and direct targeting of gut microbiome controlled neuroinflammatory pathways may potentially be disease modifying therapeutic strategies and may reduce amyloid, tau, and neurodegeneration...
Indeed, the potential beneficial effects of this type of drugs were seen for both brain–blood barrier permeable and nonpermeable statins [26]. The second aspect concerns how cholesterol modulates Aβ production in neurons, irrespective of circulating cholesterol levels. This, for the time being, ...
"But if we just prevent the plasmid transfer, then we can reduce the spread of antimicrobial resistance." "Sometimes the solution can be just to use the old stuff we already have in our closet," she added. "We just have to make the effort to test it." —D Dye Hibiscus, lemon ...
46 Thus, one might expect that high-grade nonselective proteinuria will reduce immune checkpoint inhibitor levels as seen with rituximab. Immune-related adverse effects As noted in the pharmacodynamics of immune checkpoint inhibitors, the down side of the exuberant activation of the immune system by ...
Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wodd K: Peripherally administered antibodies against amyloid beta peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2001, 6: 916-919....
These drugs could help delay, reduce, or stabilize Alzheimer’s symptoms like memory loss and confusion. They may also help control somebehavioral symptoms. Life expectancy Alzheimer’s disease typically progresses inthree stages. An early stage with minimal symptoms, a middle stage of increasing cog...
This drug, when delivered to patients in the very early stages of Alzheimer's (which makes early recognition even more important) not only eradicates amyloid from the brain, but also seems to have a modest effect on the clinical course of illness over a period of 18 months. ...